A Leading Fertility Doctor's Take on the Covid-19 Vaccine
Last updated December 15, 2020
Written by Norbert Gleicher MD, FACOG, FACS
With vaccinations against the SARS-CoV-2 virus being initiated around the world this month, it appears unlikely that this first phase of immunizations will include many infertility patients. Priority has been correctly assigned to health care providers, first responders and older individuals (males over female) with highest mortality risks from COVID-19.
Are the vaccines safe?
Yes, FDA approved vaccines can be assumed to be safe. They have been tested on thousands of people and, though side effects appear to be a little more pronounced than with traditional flu-shots, the vaccines appear extremely well tolerated. If symptoms appear, they are like those after a flu-shot: Sometimes a mild fever, muscle pains and aches like with the flu and feeling “under the weather.” These symptoms mostly last for only 1-2 days and appear more frequently after the second booster shot than after the initial inoculation. Both of the first two vaccines to come to market require two vaccinations, depending on the manufacturer, either 3 or 4 weeks apart.
Side effects of vaccines usually happen quickly. It, therefore, is reasonable that the FDA information on short-term side effects is correct. Vaccination studies, however, also have a second component, so-called post-marketing follow-up studies. Since pre-approval studies usually have only a limited follow up, they do not inform on much rarer potential long-term side effects. The FDA, therefore, requires pharma companies that produce vaccines to follow vaccinated patients for prolonged periods and immediately report all long-term side effects.
Such long-term effects are much rarer than immediate side effects, but they do occur with almost every vaccine. Concerns have been expressed that at least some of the initial vaccines (Pfizer, Moderna) may cause more long-term effects and potentially still unknown effects because they were produced with a brand-new genetic production technology, never before used in vaccines: While in prior vaccines, an antigenic part of the virus is injected, eliciting a direct immune response against the virus, with this new method of producing vaccines, the patient is injected with something that makes the body produce an antigen of the the virus, which then induces an immune response. Though based on animal studies it appears unlikely that long-term effects will be different from other vaccine production methods, the truth is, we will not know for sure until long-enough follow up exists on patients who received those new vaccines.
A potential second issue off concern has been that the family of viruses to which SARS-CoV-2 belongs is known to produce in some individuals so-called enhancing antibodies. Those are antibodies make viral diseases even worse because they disarm a big part of the immediate immune response against the virus.
Studies performed during the approval process, allegedly, have not demonstrated production of enhancing antibodies. But because such antibodies occur in only selected individuals with probably genetic predispositions, a final answer on this subject is also still outstanding, and the FDA can be assumed to follow up this issue very carefully.
How about pregnant and infertile women?
We are unaware that vaccines against the SARS-CoV-2 virus have been tested in pregnant women. If such tests have been performed, they have not been reported. The American College of Obstetricians and Gynecologists (ACOG) just announced that it is waiting for guidance from the FDA and, therefore, has not issued a guidance yet. The same applies to women in infertility treatments and children (to be further discussed below). Like ACOG, ASRM also has not issued a guidance yet. But extrapolations from greatly improved knowledge about the effects of the virus in pregnancy and from other related viruses can be made.
For example, except for very rare exceptions, the virus does not cross the placenta; yet, if the mother obtains antibody immunity early in pregnancy, this immunity is via IgG antibodies transmitted to her offspring who is born with immunity to the virus. In other words, this virus behaves not differently in that regard than common flu or other viruses. Offspring, therefore, will, likely, benefit if mothers are immunized either before or early in pregnancy. It is also reasonable to assume that, like with flu vaccinations, such immunizations also will benefit mothers. The reason is that, like the flu, COVID-19 produces in pregnancy more severe disease in women than in the non-pregnant state (even though it does not increase mortality). We, therefore, would expect pregnant women to receive certain priority in being vaccinated.
Based on what is known currently. My center, The Center for Human Reproduction recommends that all women in infertility treatment be vaccinated as early as possible and the same should apply to already pregnant women.
So-far, there have been no studies of vaccines performed in children. Since risks to children from this virus infection are so extremely low, such studies, likely, have had very low priority. More important studies are likely, addressing important questions, like should there be dosing differences between younger and older peopled (with flu vaccines, older individuals above age 60-65 require much higher dosing). Preliminary studies in older patients suggest no such differences; but it is still unclear whether that will remain the last word.
Children, therefore, as of this moment will not be vaccinated against SARS-CoV-2 virus and should under no circumstances be given an adult vaccine.
What then about individuals who already were exposed to the virus and have anti-SART-CoV-2 antibodies?
We were unable to find a clear answer to this question because the most likely answer is probably, “it depends.” Immunity to the virus, likely, depends on the level an individual expresses, both in adaptive antibody immunity and in innate cellular long-term immunity. As has been reported, antibody immunity declines over time and may, indeed, completely disappear. What happens to long-term cellular immunity is less well understood because it is so much more difficult to study.
That immunity can wear off is also demonstrated by the fact that an increasing number of second infections has been reported worldwide. Somewhat worrisome are also reports that second infections often are more severe than first infections. This observation is a potentially worrisome in view of above discussed enhancing antibodies because a more sever second infection could suggest that the increased severity may be due to enhancing antibodies developed in first infections.
Though little information currently exists in the literature regarding this question, as of this moment, we would probably recommend for most people vaccination, even in presence of already preexisting antibodies.
There is still a lot we are discovering about the vaccine, and we will continue to learn more as it is rolled out around the world. Be sure to talk to your doctor about your own personal risk and needs in relation to the vaccine.
Supplement Your Journey with 10% off
Join over 3,000 others and get research-based education, access to expert events and VIP offers.